—
C+
C+ The full Closelooknet — membership. Open the C+ overview

AstraZeneca PLC (AZN.L) — chart, structure and Closelooknet read

The Closelooknet read

AstraZeneca discovers, develops, manufactures and sells prescription medicines across oncology, cardiovascular and renal disease, respiratory and immunology, vaccines, and rare diseases. It sells through distributors and local offices across the UK, the Americas, Europe, Asia, Africa and Australasia.

Detail below: the desk's view, the earnings record, peers and the company snapshot; daily prices on the price-history tab. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for AZN.L, from the same nightly bakes the boards use. Research diary readings, not advice.

Versus its index AI Users — the name, its sleeve and the index over day, week and month

Versus its index

The name against its Closelooknet index and its own sleeve — equal-weight, nightly closes.

AI Users · as of 2026-11-10

DayWeekMonth3 months
AZN.L−1.3%+0.9%+15.4%+18.6%
Research, Design & Development−0.2%−2.8%+8.0%—
AI Users−0.1%+1.1%+5.5%—

Against the index: 0.2 pts behind on the week, 9.9 pts ahead on the month; against its Research, Design & Development sleeve 7.4 pts ahead on the month.

Returns from the index workers’ nightly closes; equal-weight sleeves. A relative reading from the research diary, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 48/100 · S&P 500 fund at 51, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-11-10
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 67th percentile of the window, -18.1% over 20 sessions. Factor regime → 2026-11-10
  • Sector × region Health care in Europe: +2.4% week · +14.5% month · +11.7% quarter · +16.3% yearThe Sector Engine cell this name lives in, from EXV4.XETRA; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-11-10
  • Sovereign pressure Index -1.67 · down 1.71 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-11-09
Who it is priced against AI Users · Research, Design & Development · 3 names with week and year-to-date

Peer group

AI Users · Research, Design & Development

Compared against AZN.L on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — AstraZeneca PLC

AZN.L in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
AstraZeneca discovers, develops, manufactures and sells prescription medicines across oncology, cardiovascular and renal disease, respiratory and immunology, vaccines, and rare diseases. It sells through distributors and local offices across the UK, the Americas, Europe, Asia, Africa and Australasia. The company is headquartered in Cambridge, England.
Where it sits in the stack
AstraZeneca sits in the AI Users index (our index of companies deploying AI at scale to strengthen their existing businesses), in the Research, Design & Development section. By February 2025 it disclosed AI use across 85% of small-molecule programmes from target to clinic, lifted output and cut lead time at its Wuxi manufacturing site, and read 3.5 million chest x-rays for early lung-nodule screening, up from 1.5 million disclosed in 2023. Earlier tools include the REINVENT model for molecule design, in use from 2020, and AiZynth retrosynthesis software, in routine use from 2021. In each case AI assists scientists and engineers rather than acting on its own.
Who it is priced against
Closelooknet groups it under AI Users · Research, Design & Development with Eli Lilly, Roche and Natera; the market also compares it with Novartis.
Why Closelooknet tracks it
AstraZeneca holds a seat in our AI Users index, under the Research, Design & Development section. It carries a Closelooknet score, but only one module is scored so far, so the score is still being built.
What the diary watches
The diary watches whether the lung-cancer AI screening reaches its stated target of five million patients by 2025, and whether the Sferical AI supercomputer announced in August 2025 shortens drug-candidate timelines toward the iLab goal of finding candidates in half the time.

AstraZeneca PLC (AZN.L) trades on the LSE exchange in UK, classified under Healthcare.

The Closelooknet company score reads 55/100 composite (momentum 60, quality 75, valuation 44) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-10-25. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Dividends and capital return trailing yield 1.72%, semi-annual · last 79.50 GBP on 2026-08-06

Dividends and capital return

What AZN.L pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 239 GBP per share · a 1.72% yield on the 2026-11-10 close 2 distributions, paid twice a year 2026-11-10
  • Change on the year −2.3% against the prior twelve months prior twelve months 245 GBP per share
  • Last distribution 79.50 GBP per share as the price series records it, within days of the ex-date 2026-08-06
  • By calendar year 2025: 245 GBP (partial) · 2026: 239 GBP to date first distribution recorded in the three-year window: 2025-02-20
  • Dividends paid, FY2025 4.97 bn GBX 24% of earnings
  • Share count −0.1% in FY2025
  • Capital returned 4.97 bn GBX · 57% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-11-11

Quick answers

What is AstraZeneca PLC (AZN.L)?

AstraZeneca PLC trades as AZN.L on the LSE exchange (UK) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-11-11.

Is AZN.L in a Closelooknet index?

Not currently — AstraZeneca PLC is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-11-11.

What is AstraZeneca PLC's Closelooknet composite score?

55 out of 100, with momentum 60, quality 75 and valuation 44 sub-scores, as of 2026-11-11. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does AZN.L trade against its moving averages?

AstraZeneca PLC trades 10.6% above its 50-day and 3.9% above its 200-day moving average (5.2% above its 20-day). As of 2026-11-10 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How is AZN.L doing against its Closelooknet index?

Over the past month AstraZeneca PLC is +15.4% against +5.5% for the AI Users — 9.9 points ahead of its index, as of 2026-11-10. Its Research, Design & Development sleeve is +8.0% over the same month. The “Versus its index” table on this page carries the day, the week and the month for the name, its sleeve and the index.

How does AstraZeneca PLC compare with its peers?

Against its peer group (AI Users · Research, Design & Development), AstraZeneca PLC (AZN.L) sits 10.2% below its 52-week high, 10.6% above its 50-day average; Eli Lilly and Company (LLY) is 2.8% below, Roche Holding AG (ROP.SW) is 1.0% below, Natera Inc (NTRA) is 26.8% below, as of 2026-11-10. Put any of them next to AZN.L in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

What does AstraZeneca PLC do?

AstraZeneca discovers, develops, manufactures and sells prescription medicines across oncology, cardiovascular and renal disease, respiratory and immunology, vaccines, and rare diseases. It sells through distributors and local offices across the UK, the Americas, Europe, Asia, Africa and Australasia. The company is headquartered in Cambridge, England. Closelooknet groups it under AI Users · Research, Design & Development with Eli Lilly, Roche and Natera; the market also compares it with Novartis. (Company snapshot of 2026-10-25.)

Where does AstraZeneca PLC sit in the AI build-out?

AstraZeneca sits in the AI Users index (our index of companies deploying AI at scale to strengthen their existing businesses), in the Research, Design & Development section. By February 2025 it disclosed AI use across 85% of small-molecule programmes from target to clinic, lifted output and cut lead time at its Wuxi manufacturing site, and read 3.5 million chest x-rays for early lung-nodule screening, up from 1.5 million disclosed in 2023. Earlier tools include the REINVENT model for molecule design, in use from 2020, and AiZynth retrosynthesis software, in routine use from 2021. In each case AI assists scientists and engineers rather than acting on its own. AstraZeneca holds a seat in our AI Users index, under the Research, Design & Development section. It carries a Closelooknet score, but only one module is scored so far, so the score is still being built. (Company snapshot of 2026-10-25.)

Does AstraZeneca PLC pay a dividend?

AstraZeneca PLC has paid 239 GBP per share over the last twelve months, paid twice a year, a trailing yield of 1.72% on the 2026-11-10 close; the last distribution recorded in the price series was 79.50 GBP on 2026-08-06. In fiscal 2025 the company paid 4.97 bn GBX in dividends, 57% of that year’s free cash flow. The share count fell 0.1% over the fiscal year. As of 2026-11-10; the "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for AZN.L, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

How to use this chart

Toolbar

  • Range — 1M to MAX on daily closes. 1D/5D switch a US stock cell to 5-minute intraday bars; index and foreign cells fall back to 1M daily with a note.
  • Grid — 1×1 up to 2×2. Cells are synchronized: pan or zoom one and the others follow the same dates; the crosshair tracks across all of them. 4 INDICES loads Rubin · HALO · AEI · AW40 side by side.
  • Type / Scale — OHLC, line or area; linear or log price axis.

Picking a series

  • Tap the box in a cell's header to browse every Closelooknet series — headline indices, sub-indices, sectors, layers of all six families — plus the constituents.
  • Or type any ticker (NVDA, 7203.T, ASML.AS …) and press Enter — it charts in the cell straight from our data lake.

Studies

  • Overlays / Oscillators rows toggle the standard set (SMA, Bollinger, RSI, MACD …) per cell.
  • Levels (stock cells) draws the structure engine's support lines — regression bands, pivot cluster, SMA-200, the active fib zone.

Drawing

  • Tap a tool (Trend, Ray, H-Line, Fib, Channel, Rect, Note), then tap the chart once per point — the shape follows your finger or cursor between taps. The chart stops panning while a tool is armed; tap the tool again to release.
  • Drawings save per symbol in this browser and travel between the terminal and the asset page.
  • Delete key removes the selected drawing · Escape cancels a half-placed one · Clear wipes the symbol.

Wave counts

  • Wave places an Elliott count: tap the origin, then each wave end. Press Enter to stop early (inside wave 3 is fine) — dotted ghost targets sketch the remaining waves at guideline ratios.
  • On stocks the scanner's machine count appears automatically in grey — it is fully editable: drag any point, double-tap a label to remove it, Delete to dismiss it for good, Adopt to bring the machine's proposal back.
  • The sequence picker switches 1-5 / A-B-C / A-E / W-X-Y-Z; 1 2 3 cycles the degree; Subdiv starts a one-degree-smaller child count inside a wave.

Sharing

  • Card exports the cell as a branded PNG — chart, drawings and levels exactly as shown.

Related in the Closelooknet universe

then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.